Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel

Pediatric Neurology

Volumn 68, Issue , 2017, Pages 18-34.e3

  Wirrell, Elaine C ^a   Laux, Linda ^b   Donner, Elizabeth ^c   Jette, Nathalie ^d,e   Knupp, Kelly ^f,g   Meskis, Mary Anne ^h   Miller, Ian ⁱ   Sullivan, Joseph ^j   Welborn, Michelle ^k   Berg, Anne T ^b  

^a MAYO CLINIC   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f University of Colorado Denver and Children s Hospital Colorado   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h Dravet Syndrome Foundation   (United States)

ⁱ NICKLAUS CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Intractable Childhood Epilepsy Alliance   (United States)

more..

Author keywords

diagnosis; Dravet syndrome; genetic testing; guidelines; questionnaire

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABIS; IMMUNOGLOBULIN; MEDICAL CANNABIS; STEROID; VALPROIC ACID; VERAPAMIL;

ALTERNATIVE MEDICINE; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DELPHI STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FAMILY ASSESSMENT; GENETIC SCREENING; HEALTH EDUCATION; HOME CARE; HOSPITAL MANAGEMENT; HUMAN; MANAGED CARE; MEDICAL EXPERT; NORTH AMERICAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; PERSONAL EXPERIENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING TEST; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TEMPORAL LOBECTOMY; TREATMENT INDICATION; VAGUS NERVE STIMULATION; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; MYOCLONUS EPILEPSY;

DELPHI TECHNIQUE; DISEASE MANAGEMENT; EPILEPSIES, MYOCLONIC; HUMANS;

EID: 85014775517     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2017.01.025     Document Type: Article

References (88)

1. 1 Wu, Y.W., Sullivan, J., McDaniel, S.S., et al. Incidence of Dravet syndrome in a US Population. Pediatrics 136 (2015), e1310–e1315.
2. 2 Bayat, A., Hjalgrim, H., Moller, R.S., The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: A population-based study from 2004 to 2009. Epilepsia 56 (2015), e36–e39.
3. 3* Brunklaus, A., Ellis, R., Reavey, E., Forbes, G.H., Zuberi, S.M., Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 135:Pt 8 (2012), 2329–2336.
4. 4 Lim, B.C., Hwang, H., Kim, H., et al. Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?. Epilepsy Res 109 (2015), 34–39.
5. 5* Hirose, S., Scheffer, I.E., Marini, C., et al. SCN1A testing for epilepsy: application in clinical practice. Epilepsia 54 (2013), 946–952.
6. 6* Chiron, C., Dulac, O., The pharmacologic treatment of Dravet syndrome. Epilepsia 52 Suppl 2 (2011), 72–75.
7. 7* Akiyama, M., Kobayashi, K., Yoshinaga, H., Ohtsuka, Y., A long-term follow-up study of Dravet syndrome up to adulthood. Epilepsia 51 (2010), 1043–1052.
8. 8* Genton, P., Velizarova, R., Dravet, C., Dravet syndrome: the long-term outcome. Epilepsia 52 Suppl 2 (2011), 44–49.
9. 9* Nabbout, R., Chemaly, N., Chipaux, M., et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis, 8, 2013, 176.
10. 10* Ragona, F., Granata, T., Dalla Bernardina, B., et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia 52 (2011), 386–392.
11. 11* Skluzacek, J.V., Watts, K.P., Parsy, O., Wical, B., Camfield, P., Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52 Suppl 2 (2011), 95–101.
12. 12 Cooper, M.S., McIntosh, A., Crompton, D.E., et al. Mortality in Dravet syndrome. Epilepsy Res 128 (2016), 43–47.
13. 13* Wirrell, E.C., Laux, L., Franz, D.N., et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia 54 (2013), 1595–1604.
14. 14* Ceulemans, B., Overall management of patients with Dravet syndrome. Dev Med Child Neurol 53 Suppl 2 (2011), 19–23.
15. 15 Wallace, A., Wirrell, E., Kenney-Jung, D.L., Pharmacotherapy for Dravet syndrome. Paediatr Drugs 18 (2016), 197–208.
16. 16 Hsu, C.C., Sandford, B.A., The Delphi technique: making sense of consensus. Pract Assess Res Eval 12 (2007), 1–8.
17. 17 Guerrini, R., Dravet syndrome: the main issues. Eur J Paediatr Neurol 16 Suppl 1 (2012), S1–S4.
18. 18* Xu, X., Zhang, Y., Sun, H., et al. Early clinical features and diagnosis of Dravet syndrome in 138 Chinese patients with SCN1A mutations. Brain Dev 36 (2014), 676–681.
19. 19* Takayama, R., Fujiwara, T., Shigematsu, H., et al. Long-term course of Dravet syndrome: a study from an epilepsy center in Japan. Epilepsia 55 (2014), 528–538.
20. 20* Dravet, C., Bureau, M., Guerrini, R., Giraud, N., Roger, J., Severe myoclonic epilepsy in infants. Roger, J., Bureau, M., Dravet, C., Dreifuss, F.E., Perret, A., Wolf, P., (eds.) Epileptic Syndromes in Infancy, Childhood and Adolescence, 2nd ed., 1992, John Libbey, London, 75–88.
21. 21 Fountain-Capal, J.K., Holland, K.D., Gilbert, D.L., Hallinan, B.E., When should clinicians order genetic testing for Dravet syndrome?. Pediatr Neurol 45 (2011), 319–323.
22. 22* Hattori, J., Ouchida, M., Ono, J., et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 49 (2008), 626–633.
23. 23* Villeneuve, N., Laguitton, V., Viellard, M., et al. Cognitive and adaptive evaluation of 21 consecutive patients with Dravet syndrome. Epilepsy Behav 31 (2014), 143–148.
24. 24* Catarino, C.B., Liu, J.Y., Liagkouras, I., et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain 134:Pt 10 (2011), 2982–3010.
25. 25* Chieffo, D., Battaglia, D., Lettori, D., et al. Neuropsychological development in children with Dravet syndrome. Epilepsy Res 95 (2011), 86–93.
26. 26* Dravet, C., Bureau, M., Dalla Bernardina, B., Guerrini, R., Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years later. Epilepsia 52 Suppl 2 (2011), 1–2.
27. 27* Barba, C., Parrini, E., Coras, R., et al. Co-occurring malformations of cortical development and SCN1A gene mutations. Epilepsia 55 (2014), 1009–1019.
28. 28* Gaily, E., Anttonen, A.K., Valanne, L., et al. Dravet syndrome: new potential genetic modifiers, imaging abnormalities, and ictal findings. Epilepsia 54 (2013), 1577–1585.
29. 29* Perez, A., Garcia-Penton, L., Canales-Rodriguez, E.J., et al. Brain morphometry of Dravet syndrome. Epilepsy Res 108 (2014), 1326–1334.
30. 30* Specchio, N., Balestri, M., Trivisano, M., et al. Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol 27 (2012), 439–444.
31. 31* Korff, C., Laux, L., Kelley, K., Goldstein, J., Koh, S., Nordli, D. Jr., Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients. J Child Neurol 22 (2007), 185–194.
32. 32* Kim, S.H., Nordli, D.R. Jr., Berg, A.T., Koh, S., Laux, L., Ictal ontogeny in Dravet syndrome. Clin Neurophysiol 126 (2015), 446–455.
33. 33 Stenhouse, S.A., Ellis, R., Zuberi, S., SCN1A genetic test for Dravet syndrome (severe myoclonic epilepsy of infancy and its clinical subtypes) for use in the diagnosis, prognosis, treatment and management of Dravet syndrome. PLoS Curr, 5, 2013.
34. 34* Brunklaus, A., Dorris, L., Ellis, R., et al. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev Med Child Neurol 55 (2013), 154–161.
35. 35* Brunklaus, A., Zuberi, S.M., Dravet syndrome–from epileptic encephalopathy to channelopathy. Epilepsia 55 (2014), 979–984.
36. 36* Camfield, P., Camfield, C., Nolan, K., Helping families cope with the devastation of Dravet syndrome. Eur J Paediatr Neurol 16 Suppl 1 (2012), S9–S12.
37. 37* Ragona, F., Cognitive development in children with Dravet syndrome. Epilepsia 52 Suppl 2 (2011), 39–43.
38. 38* Casse-Perrot, C., Wolff, M., Dravet, C., Neuropsychological aspects of severe myoclonic epilepsy in infancy. Jambaque, I., Lassonde, M., Dulac, O., (eds.) Neuropsychology of Childhood Epilepsy, 2001, Kluwer Academic/Plenum Publishers, New York, 131–140.
39. 39* Wolff, M., Casse-Perrot, C., Dravet, C., Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 47 Suppl 2 (2006), 45–48.
40. 40 Wirrell, E.C., Treatment of Dravet syndrome. Can J Neurol Sci 43 Suppl 3 (2016), S13–S18.
41. 41* Dressler, A., Trimmel-Schwahofer, P., Reithofer, E., et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. Epilepsy Res 109 (2015), 81–89.
42. 42 Inoue, Y., Ohtsuka, Y., S.-S. Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res 113 (2015), 90–97.
43. 43 Chiron, C., Marchand, M.C., Tran, A., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356 (2000), 1638–1642.
44. 44* Kassai, B., Chiron, C., Augier, S., et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 49 (2008), 343–348.
45. 45* Inoue, Y., Ohtsuka, Y., Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res 108 (2014), 725–731.
46. 46* Coppola, G., Capovilla, G., Montagnini, A., et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 49 (2002), 45–48.
47. 47* Nieto-Barrera, M., Candau, R., Nieto-Jimenez, M., Correa, A., delPortal, L.R., et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 9 (2000), 590–594.
48. 48* Kroll-Seger, J., Portilla, P., Dulac, O., Chiron, C., et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 37 (2006), 325–329.
49. 49* Striano, P., Coppola, A., Pezzella, M., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 69 (2007), 250–254.
50. 50* Tanabe, T., Awaya, Y., Matsuishi, T., et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)–a nationwide questionnaire survey in Japan. Brain Dev 30 (2008), 629–635.
51. 51* Oguni, H., Hayashi, K., Oguni, M., et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia 35 (1994), 1140–1145.
52. 52* Lotte, J., Haberlandt, E., Neubauer, B., Staudt, M., Kluger, G.J., Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics 43 (2012), 17–21.
53. 53* Mueller, A., Boor, R., Coppola, G., et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav 21 (2011), 282–284.
54. 54* Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., Dulac, O., Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39 (1998), 508–512.
55. 55* Thanh, T.N., Chiron, C., Dellatolas, G., et al. (Trans.) Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome) Arch Pediatr 9 (2002), 1120–1127.
56. 56 Chipaux, M., Villeneuve, N., Sabouraud, P., et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure 19 (2010), 190–194.
57. 57* Caraballo, R.H., Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia 52 Suppl 2 (2011), 79–82.
58. 58* Laux, L., Blackford, R., The ketogenic diet in Dravet syndrome. J Child Neurol 28 (2013), 1041–1044.
59. 59* Kang, H.C., Kim, Y.J., Kim, D.W., Kim, H.D., Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 46 (2005), 272–279.
60. 60* Nabbout, R., Copioli, C., Chipaux, M., et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 52 (2011), e54–e57.
61. 61* Zamponi, N., Passamonti, C., Cappanera, S., Petrelli, C., Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol 15 (2011), 8–14.
62. 62* Rossignol, E., Lortie, A., Thomas, T., et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure 18 (2009), 34–37.
63. 63* Shahwan, A., Bailey, C., Maxiner, W., Harvey, A.S., Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia 50 (2009), 1220–1228.
64. 64* Bremer, A., Lossius, M.I., Nakken, K.O., Dravet syndrome–considerable delay in making the diagnosis. Acta Neurol Scand 125 (2012), 359–362.
65. 65* Orosz, I., McCormick, D., Zamponi, N., et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia 55 (2014), 1576–1584.
66. 66 Dlouhy, B.J., Miller, B., Jeong, A., Bertrand, M.E., Limbrick, D.D. Jr., Smyth, M.D., Palliative epilepsy surgery in Dravet syndrome-case series and review of the literature. Childs Nerv Syst 32 (2016), 1703–1708.
67. 67* Porter, B.E., Jacobson, C., Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29 (2013), 574–577.
68. 68 Press, C.A., Knupp, K.G., Chapman, K.E., Parental reporting of response to oral cannabis extract for treatment of refractory epilepsy. Epilepsy Behav 45 (2015), 49–52.
69. 69 Devinsky, O., Marsh, E., Friedman, D., et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15 (2016), 270–278.
70. 70* Meador, K.J., Seizure reduction with fluoxetine in Dravet syndrome. Epilepsy Behav Case Rep 2 (2014), 54–56.
71. 71* Nicita, F., Spalice, A., Papetti, L., Nikanorova, M., Iannetti, P., Parisi, P., Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure 23 (2014), 36–40.
72. 72* Rodda, J.M., Scheffer, I.E., McMahon, J.M., Berkovic, S.F., Graham, H.K., Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol 69 (2012), 873–878.
73. 73* Rilstone, J.J., Coelho, F.M., Minassian, B.A., Andrade, D.M., Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia 53 (2012), 1421–1428.
74. 74* Fasano, A., Borlot, F., Lang, A.E., Andrade, D.M., Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. Neurology 82 (2014), 2250–2251.
75. 75* Dhamija, R., Erickson, M.K., St Louis, E.K., Wirrell, E., Kotagal, S., Sleep abnormalities in children with Dravet syndrome. Pediatr Neurol 50 (2014), 474–478.
76. 76 Van de Vel, A., Cuppens, K., Bonroy, B., et al. Non-EEG seizure detection systems and potential SUDEP prevention: State of the art: Review and update. Seizure 41 (2016), 141–153.
77. 77 Maguire, M.J., Jackson, C.F., Marson, A.G., Nolan, S.J., Treatments for the prevention of sudden unexpected death in epilepsy (SUDEP). Cochrane Database Syst Rev, 7, 2016, CD011792.
78. 78 Tovar Quiroga, D.F., Britton, J.W., Wirrell, E.C., Patient and caregiver view on seizure detection devices: A survey study. Seizure 41 (2016), 179–181.
79. 79 Nolan, K.J., Camfield, C.S., Camfield, P.R., Coping with Dravet syndrome: parental experiences with a catastrophic epilepsy. Dev Med Child Neurol 48 (2006), 761–765.
80. 80 Nolan, K., Camfield, C.S., Camfield, P.R., Coping with a child with Dravet syndrome: insights from families. J Child Neurol 23 (2008), 690–694.
81. 81 Djemie, T., Weckhuysen, S., von Spiczak, S., et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genomic Med 4 (2016), 457–464.
82. 82 Wallace, R., A plethora of SCN1A mutations: what can they tell us?. Epilepsy Curr 5 (2005), 17–20.
83. 83* Spatola, M., Jeannet, P.Y., Pollo, C., Wider, C., Labrum, R., Rossetti, A.O., Effect of vagus nerve stimulation in an adult patient with Dravet syndrome: contribution to sudden unexpected death in epilepsy risk reduction?. Eur Neurol 69 (2013), 119–121.
84. 84* Andrade, D.M., Hamani, C., Lozano, A.M., Wennberg, R.A., Dravet syndrome and deep brain stimulation: seizure control after 10 years of treatment. Epilepsia 51 (2010), 1314–1316.
85. 85 Cross JH, Devinsky O, Laux L, et al. Cannabidiol (CBD) reduces convulsive seizure frequency in Dravet syndrome: Results of a multi-centered, randomized, controlled study (GWPCARE1). Paper presented at: 2016 American Epilepsy Society Annual Meeting; December 2-6, 2016; Houston, TX. Abstract 2.362. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/find/cannabidiol/0/0/0. Accessed February 17, 2017.
86. 86 Hartman, A.L., Devore, C.D., Doerrer, S.C., Rescue medicine for epilepsy in education settings. Pediatrics, 137, 2016.
87. 87 Devinsky, O., Hesdorffer, D.C., Thurman, D.J., Lhatoo, S., Richerson, G., Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol 15 (2016), 1075–1088.
88. 88 Lux, A.L., Osborne, J.P., A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 45 (2004), 1416–1428 *Article also included in literature review sent to panelists.